학술논문
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial
Document Type
Article
Author
Shaw, Robert H; Liu, Xinxue; Stuart, Arabella S V; Greenland, Melanie; Aley, Parvinder K; Andrews, Nick J; Cameron, J Claire; Charlton, Sue; Clutterbuck, Elizabeth A; Collins, Andrea M; Dejnirattisai, Wanwisa; Dinesh, Tanya; Faust, Saul N; Ferreira, Daniela M; Finn, Adam; Green, Christopher A; Hallis, Bassam; Heath, Paul T; Hill, Helen; Lambe, Teresa; Lazarus, Rajeka; Libri, Vincenzo; Long, Fei; Mujadidi, Yama F; Plested, Emma L; Morey, Ella R; Provstgaard-Morys, Samuel; Ramasamy, Maheshi N; Ramsay, Mary; Read, Robert C; Robinson, Hannah; Screaton, Gavin R; Singh, Nisha; Turner, David P J; Turner, Paul J; Vichos, Iason; Walker, Laura L; White, Rachel; Nguyen-Van-Tam, Jonathan S; Snape, Matthew D; Munro, Alasdair P.S.; Bartholomew, Jazz; Presland, Laura; Horswill, Sarah; Warren, Sarah; Varkonyi-Clifford, Sophie; Saich, Stephen; Adams, Kirsty; Ricamara, Marivic; Turner, Nicola; Yee Ting, Nicole Y.; Whittley, Sarah; Rampling, Tommy; Desai, Amisha; Brown, Claire H.; Qureshi, Ehsaan; Gokani, Karishma; Naker, Kush; Kellett Wright, Johanna K.; Williams, Rachel L.; Riaz, Tawassal; Penciu, Florentina D.; Carson, Amy; Di Maso, Claudio; Mead, Gracie; Howe, Elizabeth G.; Vichos, Iason; Ghulam Farooq, Mujtaba; Noristani, Rabiullah; Yao, Xin L.; Oldfield, Neil J.; Hammersley, Daniel; Belton, Sue; Royal, Simon; San Francisco Ramos, Alberto; Hultin, Cecilia; Galiza, Eva P.; Crook, Rebecca; Bula, Marcin; Fyles, Fred; Burhan, Hassan; Maelin, Flora; Hughes, Elen; Okenyi, Emmanuel
Source
The Lancet Respiratory Medicine; 20220101, Issue: Preprints
Subject
Language
ISSN
22132600; 22132619
Abstract
Priming COVID-19 vaccine schedules have been deployed at variable intervals globally, which might influence immune persistence and the relative importance of third-dose booster programmes. Here, we report exploratory analyses from the Com-COV trial, assessing the effect of 4-week versus 12-week priming intervals on reactogenicity and the persistence of immune response up to 6 months after homologous and heterologous priming schedules using the vaccines BNT162b2 (tozinameran, Pfizer/BioNTech) and ChAdOx1 nCoV-19 (AstraZeneca).